We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Advisory Contract Between Medwell Capital and Spectral Diagnostics Increases
News

Advisory Contract Between Medwell Capital and Spectral Diagnostics Increases

Advisory Contract Between Medwell Capital and Spectral Diagnostics Increases
News

Advisory Contract Between Medwell Capital and Spectral Diagnostics Increases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Advisory Contract Between Medwell Capital and Spectral Diagnostics Increases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medwell Capital Corp. has announced that the service agreement under which Medwell provides clinical, regulatory and capital markets consulting services to Spectral Diagnostics has been increased to $1.5 million per year, from $1.0 million, effective January 2011, in exchange for an increased level of service.

"We look forward to providing Spectral with additional clinical and regulatory resources, as well as enhancing their IR/PR initiatives as they advance their U.S. phase III clinical trial for Toraymyxin in patients with severe sepsis," said Kevin Giese, President and CEO of Medwell Capital.

"Our recent $1.7 million additional investment in Spectral, as announced on March 28, 2011, reflects our confidence in Spectral's technology and the large market opportunity that exists for Spectral in the area of sepsis."

Advertisement